Serum Adipokine Levels in Type 1 Diabetic Patients: Association with Carotid Intima Media Thickness

Abstract

Background:

Adipokines are markers of insulin resistance and play a role in the atherosclerotic process. The association of adipokines with the macrovascular complications of type 1 diabetes mellitus (DM) needs to be determined. The aim of this study was to measure serum adiponectin, leptin, and resistin levels in type 1 DM patients and investigate their relationship with carotid intima media thickness (CIMT), a clinical marker of atherosclerosis.

Methods:

Seventy-five type 1 DM patients and 115 sex and age-matched healthy controls were included in the study. Serum adiponectin, leptin, and resistin levels were measured by the enzyme-linked immunosorbent assay (ELISA method). CIMT was assessed by Doppler ultrasonography

Results:

Adiponectin levels in diabetics were higher (25.8±14.8 μg/mL vs. 5.5±7.3 μg/mL; P<0.0001) and leptin levels were lower than controls (9.4±6.2 ng/mL vs. 12.8±8.6 ng/mL; P=0.01). Resistin levels were also higher in the diabetic group compared to controls (2.1±1.4 ng/mL vs. 1.6±0.8 ng/mL; P=0.04). Adiponectin was correlated negatively with CIMT (r=−0.24, P=0.03), age (r=−0.30, P=0.02), BMI (r=−0.33, P=0.02), waist-to-hip ratio (WHR) (r=−0.38, P=0.01) and positively with creatinine (r=0.44, P=0.004). Leptin levels were correlated with total cholesterol (r=0.53, P=0.01) and high-density lipoprotein (HDL) (r=0.67, P=0.001). Resistin was correlated with CIMT (r=0.24, P=0.03) and systolic blood pressure (r=0.48, P=0.009). Multivariate analysis revealed resistin and creatinine to be independent predictors of CIMT among adiponectin, leptin, resistin, WHR, glycosylated hemoglobin (HbA1c), and creatinine.

Conclusions:

Increased adiponectin correlates negatively and resistin positively with CIMT in type 1 diabetic patients, but adjusting for other known predictors reveals only resistin to be associated with subclinical atherosclerosis in this group of patients.

Get full access to this article

View all access options for this article.

References

Krolewski

, Kosinski

, Warram

et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol, 1987; 59:750–755.

Soedamah-Muthu

, Chaturvedi

, Toeller

et al. EURODIAB Prospective Complications Study Group. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care, 2004; 27:530–537.

Kilpatrick

, Rigby

, Atkin

. Insulin resistance, the metabolic syndrome and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care, 2007; 30:707–712.

Orchard

, Olson

, Erbey

et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care, 2003; 26:1374–1379.

Huerta

. Adiponectin and leptin: Potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord, 2006; 7:187–196

Goldstein

, Scalia

. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab, 2004; 89:2563–2568

Kubota

, Terauchi

, Yamauchi

et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 2002; 277:25863–25866.

Pischon

, Girman

, Hotamisligil

et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 2004; 291:1730–1737.

Siegrist-Kaiser

, Pauli

, uge-Aubry

et al. Direct effects of leptin on brown and white adipose tissue. J Clin Invest, 1997; 100:2858–2864.

10.

Kieffer

, Habener

. The adipoinsular axis: Effects of leptin on pancreatic beta-cells. Am J Physiol Endocrinol Metab, 2000; 278:E1–E14.

11.

Leyva

, Godsland

, Ghatei

et al. as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol, 1998; 18:928–933.

12.

Steppan

, Bailey

, Bhat

et al. The hormone resistin links obesity to diabetes. Nature, 2001; 409:307–312.

13.

Kawanami

, Maemura

, Takeda

et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: A new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun, 2004; 314:415–419.

14.

Verma

, Li

, Wang

et al. Resistin promotes endothelial cell activation: Further evidence of adipokine-endothelial interaction. Circulation, 2003; 108:736–740.

15.

Youn

, Yu

, Park

et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2004; 89:150–156.

16.

Hasegawa

, Ohta

, Ichida

et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol, 2005; 42:104–109.

17.

Frystyk

, Tarnow

, Hansen

et al. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 2005; 48:1911–1918.

18.

Imagawa

, Funahashi

, Nakamura

et al. Elevated serum concentration of adipose-derived factor, adiponectin, in patients with type 1 diabetes. Diabetes Care, 2002; 25:1665–1666

19.

Hadjadj

, Aubert

, Fumeron

et al. SURGENE Study Group; DESIR Study Group. Increased plasma adiponectin concentrations are associated with microangiopathy in type 1 diabetic subjects. Diabetologia, 2005; 48:1088–1092.

20.

Orchard

, Dorman

, Maser

et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes, 1990; 39:1116–1124.

21.

Roden

, Ludwig

, Nowotny

et al. Relative hypoleptinemia in patients with type 1 and type 2 diabetes mellitus. Int J Obes Relat Metab Disord, 2000; 24:976–981.

22.

Fehmann

, Heyn

. Plasma resistin levels in patients with type 1 and type 2 diabetes mellitus and in healthy controls. Horm Metab Res, 2002; 34:671–673.

23.

Schäffler

, Büchler

, Müller-Ladner

et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res, 2004; 36:702–707.

24.

Schalkwijk

, Chaturvedi

, Schram

et al. EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab, 2006; 91:129–135.

25.

Abd El-Maksoud

, El Hefnawy

et al. Early predictors of microvascular complications in type 1 diabetic patients. Clin Biochem, 2009; 42:1401–1406.

26.

Jorsal

, Tarnow

, Frystyk

et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type 1 diabetes and diabetic nephropathy. Kidney Int, 2008; 74:649–654.

27.

Shetty

, Economides

, Horton

et al. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 2004; 27:2450–2457.

28.

Costacou

, Zgibor

, Evans

et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia, 2005; 48:41–48.

29.

Tan

, Xu

, Chow

et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab, 2004; 89:765–769.

30.

Fernández-Real

, Castro

, Vázquez

et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care, 2004; 27:739–745.

31.

Atabek

, Kurtoglu

, Demir

et al. Relation of serum leptin and insulin-like growth factor-1 levels to intima-media thickness and functions of common carotid artery in children and adolescents with type 1 diabetes. Acta Paediatr, 2004; 93:1052–1057.

32.

Williams

, Erbey

, Becker

et al.

Can clinical factors estimate insulin resistance in type 1 diabetes?

Diabetes, 2000; 49:626–632.

33.

Pajvani

, Du

, Combs

et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem, 2003; 278:9073–9085.

34.

Kowalska

, Straczkowski

, Nikołajuk

et al. Plasma adiponectin and E-selectin concentrations in patients with coronary heart disease and newly diagnosed disturbances of glucose metabolism. Adv Med Sci, 2006; 51:94–97.

35.

Leth

, Andersen

, Frystyk

et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab, 2008; 93:3186–3191.

36.

Reilly

, Iqbal

, Schutta

et al. Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab, 2004; 89:3872–3878.

37.

, Park

, Hyon

et al. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J, 2007; 71:868–873.